Retrospective analysis of omalizumab treatment in 16 cholinergic urticaria (CholU) patients revealed effectiveness in two third of the patients, especially in female patients. Most non-responders to standard-dosed omalizumab benefited from updosing. Non-responders raise the question of different pathomechanisms in these patients. (Source: Journal of Allergy and Clinical Immunology)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2yaFLHE
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.